Ginkgo Biloba Benefits: What a 90 mg Standardized Extract Can - and Cannot - Promise

QUICK ANSWER Biogenique Ginkgo biloba provides 90 mg of a 50:1 leaf extract per tablet, standardized to 25% flavonoid glycosides and 6% terpene lactones. Its Canadian label says it helps enhance cognitive function and memory in adults and supports peripheral circulation. Those are licensed uses, not a guarantee of a noticeable effect. The strongest 2026 evidence finds little or no benefit for mild cognitive impairment, uncertain evidence for subjective complaints, and only low-certainty possible benefit in dementia. Most major trials used 120 to 240 mg daily of different standardized extracts, so their results cannot be transferred directly to this 90 mg product.

First, identify the exact Ginkgo product

This guide covers Biogenique Ginkgo biloba, NPN 80091428: 90 tablets, each supplying 90 mg of a standardized 50:1 Ginkgo biloba leaf extract. It is a single-ingredient tablet. It is not the same as the brand's multi-ingredient cognitive, circulation or vision formulas, even when those pages refer to the same ginkgo licence or ingredient.

Exact identification matters because ginkgo research is formulation-sensitive. Different products can use different extracts, marker ranges, daily doses, raw-material controls and non-medicinal ingredients. The phrase 'ginkgo was studied' is not enough to establish that a particular bottle matches the research.

What is a standardized Ginkgo biloba extract?

Ginkgo supplements are generally made from processed leaf extracts. Standardization means the finished extract is adjusted or selected to contain stated levels of chemical marker groups. On the reviewed label, those markers are 25% flavonoid glycosides and 6% terpene lactones. In one 90 mg tablet, those percentages correspond arithmetically to about 22.5 mg of flavonoid glycosides and 5.4 mg of terpene lactones, although the provided lot certificate does not report a finished-product assay result for either marker.

Standardization improves description and can support batch consistency when verified by appropriate testing. It does not by itself prove better absorption, a clinically relevant dose or an outcome for memory. It also does not make all standardized extracts equivalent. The frequently studied proprietary extract EGb 761 is usually described as 24% flavone glycosides and 6% terpene lactones, and trials commonly used 120 or 240 mg per day. Similar marker percentages do not establish identical chemistry or clinical interchangeability.

What exactly is in the Biogenique tablet?

Medicinal ingredient: Ginkgo biloba leaf extract, 50:1, 90 mg per tablet.
Dried-herb equivalent stated on the label: 4,500 mg per tablet.
Standardized markers: 25% flavonoid glycosides and 6% terpene lactones.
Reviewed adult dose: one tablet daily.
Container: 90 tablets, equal to 90 labelled daily doses.
Canadian product identifier: NPN 80091428.
Non-medicinal ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and stearic acid.

Product fact	Reviewed value	Practical meaning
Medicinal ingredient	Ginkgo biloba 50:1 leaf extract, 90 mg	Equivalent to 4,500 mg dried leaf by extraction ratio
Standardization	25% flavonoid glycosides; 6% terpene lactones	Marker percentages describe composition, not guaranteed clinical effect
Dose and identifier	Adults: 1 tablet daily; 90 tablets; NPN 80091428	A labelled bottle supplies 90 daily doses

What does 50:1 and 'equivalent to 4,500 mg' mean?

A 50:1 ratio means that the manufacturer represents 50 parts of starting dried plant material as yielding one part of extract under the stated process. Multiplying 90 mg by 50 gives the 4,500 mg dried-herb equivalent shown on the label. The tablet does not physically contain 4.5 g of leaf powder, and the equivalence number should not be compared with a raw-herb dose as if the two materials were identical.

Extraction ratio also does not reveal the solvent system, full chemical fingerprint, ginkgolic-acid level, bioavailability or clinical performance. For readers, the most useful formulation facts are the actual 90 mg extract amount, its 25/6 marker standardization, the labelled once-daily dose and the exact NPN.

What is this NPN label actually licensed to say?

The reviewed Canadian label states that the product helps enhance cognitive function and memory in adults and supports peripheral circulation. Those claims are the appropriate starting point for product copy. They should be repeated with the qualifying language 'helps' and 'supports' rather than rewritten as treatment, prevention or guaranteed performance claims.

An NPN means Health Canada authorized the product for sale under specified conditions. It does not mean that every broad claim about ginkgo is approved, that one product has been tested in a clinical trial, or that the licensed use has the same certainty as a prescription-drug indication. Current licence wording, dose, risk information and label directions remain product-specific.

Three evidence layers that should not be blended

Evidence layer	What can be said	What cannot be inferred
Reviewed label and licence	Licensed adult uses include cognitive function, memory and peripheral circulation support.	The NPN does not mean the product prevents dementia, treats Alzheimer's disease or works for every adult.
Human research	Ginkgo extracts have been tested in healthy adults, cognitive complaints, MCI, dementia and peripheral artery disease.	Studies using 120 to 240 mg/day or the named extract EGb 761 do not prove an effect for this 90 mg 25/6 extract.
Lot 240916 COA	The listed physical, microbial and heavy-metal tests met that document's specifications.	It does not show an identity or marker assay, ginkgolic-acid result, absorption test, clinical potency or the quality of every lot.

The central dose-matching problem

The Biogenique dose is 90 mg once daily. Many prominent cognitive trials used 120 mg once daily, 120 mg twice daily or 240 mg once daily. That makes the tested daily amount about 1.3 to 2.7 times the labelled Biogenique dose. Some positive dementia studies also focused on EGb 761, a defined proprietary extract rather than any product that happens to list ginkgo and similar marker percentages.

This gap cuts both ways. A positive 240 mg trial cannot be used to promise that 90 mg will reproduce the result. A negative 240 mg prevention trial also does not test this exact tablet, although it strongly argues against claiming that ginkgo supplements prevent dementia. The responsible conclusion is product-specific: Biogenique's licensed 90 mg formula may be marketed within its authorized wording, but it is not a direct match to the best-known clinical regimens.

PRACTICAL INTERPRETATION Treat the 25/6 standardization as a useful composition fact, not as proof that one 90 mg tablet is clinically equivalent to 120 or 240 mg of EGb 761. Keep trial doses and extract names beside every evidence claim.

What does the evidence show for healthy adults with memory concerns?

Results are mixed and do not justify a universal 'memory booster' promise. A six-week randomized JAMA trial in healthy adults aged 60 and older used 120 mg per day and found no benefit on standard tests of learning, memory, attention or concentration, and no benefit in ratings by participants or companions. Other smaller trials using different doses and measures have reported selective improvements, but selective test findings are not the same as a reliable everyday memory effect.

The 2026 Cochrane review also found very uncertain evidence for people with subjective cognitive complaints. That population is closer to many supplement shoppers than people with diagnosed dementia. A fair consumer message is that a noticeable memory benefit is not established, especially for this untested 90 mg product.

What about mild cognitive impairment and dementia?

The 2026 Cochrane review included 82 studies with 10,613 participants; only four studies were at low risk of bias in all assessed domains. For mild cognitive impairment, moderate-certainty evidence indicated little or no effect at six months on global clinical status, cognition or activities of daily living. Ginkgo should not be described as a treatment for MCI on that evidence.

For diagnosed dementia, the same review found low-certainty evidence of possible small-to-moderate benefits at six months in global status, cognition and daily function. Results were highly inconsistent across studies. These findings do not support self-treatment, do not show that ginkgo slows the underlying disease, and do not establish benefit for Biogenique 90 mg. People with new or worsening cognitive symptoms need clinical assessment for reversible causes and appropriate care.

Does ginkgo prevent dementia?

No reliable evidence supports that claim. The Ginkgo Evaluation of Memory trial randomized 3,069 adults aged 75 or older to 120 mg of ginkgo twice daily or placebo and followed them for a median of 6.1 years. Ginkgo did not reduce all-cause dementia, Alzheimer disease or progression from mild cognitive impairment to dementia. The intervention dose was 240 mg per day - far above this product's 90 mg label - yet prevention still was not demonstrated.

Marketing should therefore avoid 'protects against Alzheimer's,' 'prevents cognitive decline,' 'slows brain aging' and similar phrases. Supporting a licensed adult memory claim is not the same as preventing a disease.

What does 'supports peripheral circulation' mean?

Peripheral circulation refers to blood flow outside the heart and central circulation, particularly through the limbs. The label permits a support claim, but it does not authorize treatment of peripheral artery disease, blood clots, stroke, cold hands and feet from any cause, or walking pain due to blocked arteries.

Clinical evidence for intermittent claudication is not persuasive. A Cochrane review concluded that ginkgo did not provide a clinically significant benefit for people with peripheral arterial disease. Leg pain with walking, non-healing wounds, colour change, one-sided swelling or sudden coldness requires medical evaluation rather than supplement substitution.

Plausible mechanisms are not outcomes

Ginkgo flavonoids and terpenes are often discussed in relation to antioxidant activity, vascular signalling, blood rheology and neuronal pathways. These mechanisms can help explain why researchers test an extract, but a laboratory mechanism does not establish that a 90 mg tablet improves memory, increases oxygen delivery to the brain or prevents vascular disease in humans.

The product page currently uses broad phrases about purity, potency, absorption and performance. Those are separate substantiation questions. The reviewed label and COA do not contain a comparative absorption study or clinical trial of this finished product, so the blog should not convert mechanism or manufacturing language into a superior-performance claim.

How to take this exact product

The reviewed label directs adults to take one tablet daily. It does not specify morning versus evening, with food versus without food, or a mandatory trial duration. Follow the current package directions and do not double the dose to imitate a 180 or 240 mg research regimen. A different research dose is not a personal dosing recommendation.

At one tablet daily, a 90-tablet bottle lasts 90 days. If memory concerns are persistent, progressive or interfering with daily life, do not wait for a bottle to be finished before seeking assessment. Medication effects, sleep disorders, depression, thyroid disease, nutrient deficiencies and neurological conditions can all affect cognition and require different management.

Label cautions and medication interactions

The reviewed label says to consult a health-care practitioner before use during pregnancy or breastfeeding, or when taking medication for diabetes, high blood pressure or seizures. It says not to use the product with health products that affect blood coagulation because this may increase the risk of spontaneous bleeding. Keep it out of reach of children and do not use a bottle with a missing or broken outer seal.

That warning deserves literal treatment. Do not soften it to 'usually safe with blood thinners.' A 2011 meta-analysis of randomized trials did not find a higher bleeding risk from standardized extracts on average, but trial averages do not erase product-specific contraindications, case reports or individual interaction risk. Anyone using anticoagulants, antiplatelet products or multiple interacting medicines should have the full regimen reviewed by a qualified clinician or pharmacist.

Health Canada's cardiac-arrhythmia signal

Health Canada published a 2021 safety review after receiving domestic and international reports of cardiac arrhythmias associated with oral ginkgo products. The reports could not prove causation and were vulnerable to confounding, but the agency described a suspected association and asked health professionals to remain alert and report cases. The product's reviewed label does not contain a specific arrhythmia warning.

A reader who develops palpitations, fainting, marked dizziness, chest pain or a new irregular heartbeat while using any supplement should seek timely medical advice. The blog should not present absence of an arrhythmia line on this label as proof that the risk is impossible.

The 2025 Canadian draft chemical assessment

Health Canada and Environment and Climate Change Canada published a draft assessment in January 2025 that proposed potential human-health concerns from certain ginkgo-extract exposures, including some oral supplements. The public information page identifies liver cancer and effects on growth and development as the hazard concerns under evaluation and advises people to limit consumption, follow product labels and keep products away from children and pets.

The assessment is explicitly described as draft, not final. It is a population-level chemical risk assessment, not proof that this product causes cancer in a user, and it is distinct from the product's NPN. It should not be sensationalized or omitted. As of the August 2026 review date, the official page still says the government is evaluating the evidence before a final conclusion and possible risk-management actions.

What the lot-specific certificate of analysis adds

The reviewed certificate covers Biogenique Ginkgo Biloba lot 240916, manufactured in September 2024 and listed to expire in August 2027. It reports a mean tablet weight of 222.00 mg, 0.23% friability, 4.92 mm thickness, 7 kgf hardness and 27-minute disintegration, all within the certificate's stated specifications.

For the same lot, total plate count and yeast and mould were each reported below 10 CFU/g. E. coli, Salmonella, S. aureus and P. aeruginosa were reported negative. Arsenic and lead were reported at 0.001 micrograms/kg body weight/day, while cadmium and mercury were below 0.001, against the certificate's listed limits. Those results are useful evidence for the tested categories on lot 240916 only.

The certificate repeats the 90 mg 50:1 formula and 25/6 marker claims but does not display a finished-product identity test, flavonoid-glycoside assay result, terpene-lactone assay result, ginkgolic-acid result, dissolution test, stability result or comparative absorption test. It therefore does not independently substantiate potency, high absorption, clinical effectiveness or every-batch performance.

Document-control issues to correct before publication

The reviewed label artwork describes a 90-tablet product and gives a tablet dose, but its medicinal-ingredient panel says 'Each capsule contains.' The Health Canada licence identifies the dosage form as a tablet. Correct the capsule/tablet wording in controlled artwork before relying on it for public copy.

The artwork sample shows lot 240539 with an April 2027 expiry, while the available COA and the public quality-control page identify lot 240916 with an August 2027 expiry. A COA for one lot should not be presented as the certificate for another lot. The public product page also spells the strength line 'Ginko Biloba 90 MG' in some locations. Standardize the product name to Ginkgo biloba and ensure the certificate link resolves to the lot being sold.

Frequently asked questions

Is 4,500 mg of ginkgo in each tablet?

No. The tablet contains 90 mg of a 50:1 extract. The 4,500 mg figure is the labelled dried-leaf equivalent calculated from that extraction ratio. It is not 4.5 g of leaf powder physically packed into the tablet.

Is 90 mg the same as the extract used in clinical trials?

Not necessarily. The product is standardized to 25% flavonoid glycosides and 6% terpene lactones, but many major trials used 120 to 240 mg/day of EGb 761 or another defined preparation. Similar marker percentages do not prove identical raw material, manufacturing, chemical profile, dose or clinical effect.

Does Ginkgo biloba prevent Alzheimer's disease?

No preventive effect was shown in the large GEM trial, which tested 240 mg/day for a median of 6.1 years. This product is not licensed as an Alzheimer's-prevention product, and its 90 mg dose has not been shown to prevent dementia.

Can I take it with a blood thinner?

Do not override the label. The reviewed wording says not to use the product with health products that affect blood coagulation because of possible spontaneous bleeding. Ask a clinician or pharmacist to review prescriptions, over-the-counter medicines and supplements rather than deciding from a generic interaction list.

How long before memory benefits appear?

There is no reliable universal timeline, and a noticeable benefit is not established for this 90 mg product. The reviewed label does not specify a minimum duration. Progressive or function-limiting memory change warrants medical assessment rather than an extended self-directed trial.

Is the product COA proof of potency?

The reviewed lot 240916 certificate supports the listed physical, microbial and heavy-metal results. It does not show numerical assay results for the 25% flavonoid-glycoside or 6% terpene-lactone markers, nor a ginkgolic-acid result. Calling it proof of potency or superior absorption would go beyond the document.

The bottom line

Biogenique Ginkgo biloba is a clearly specified Canadian natural health product: one 90 mg tablet daily, made from a 50:1 leaf extract standardized to 25% flavonoid glycosides and 6% terpene lactones, under NPN 80091428. Its label supports carefully qualified adult claims for cognitive function, memory and peripheral circulation.

The research is less simple than the front label. The strongest current review finds little or no benefit for MCI, uncertain evidence for subjective complaints and only low-certainty possible benefit in dementia. A large trial did not prevent dementia, and peripheral-artery evidence is not clinically persuasive. The 90 mg Biogenique dose is also below the 120 to 240 mg regimens used in many trials. The most useful article is therefore exact, modest and safety-forward: explain the standardized formula, keep the licensed wording, show the dose mismatch, and do not turn an NPN or a limited COA into proof of clinical performance.

PUBLICATION GATE Use only the licensed 'helps enhance cognitive function and memory in adults' and 'supports peripheral circulation' wording. Do not claim dementia or Alzheimer's prevention, MCI treatment, improved brain oxygen delivery, clinically proven memory boosting, superior absorption or guaranteed results. Correct 'Each capsule' to 'Each tablet,' fix the 'Ginko' spelling on the product page, and match the public COA to the lot being sold. Qualify the 2021 arrhythmia signal and 2025 draft chemical assessment accurately. Do not call lot 240916 potency-tested unless marker assays and relevant specifications are added to the certificate. Recheck the live licence, label, safety page and product availability on the publication date.

Product link

View Biogenique Ginkgo biloba 90 mg

Sources

Educational information only; not medical advice. Natural health product claims, directions and risk statements are product- and licence-specific. Always read the current label.